Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

News
AstraZeneca Combo Lung Disease Therapy Fails to Win FDA Approval
10/01/2019
According to AstraZeneca, the FDA has declined to approve its combination therapy used for the treatment of smoker's lung.
According to AstraZeneca, the FDA has declined to approve its combination therapy used for the treatment of smoker's lung.
According to AstraZeneca, the...
10/01/2019
Pharmacy Learning Network

Advertisement

News
U.S. Authorities Investigate as Many as 11 Deaths at Veterans Hospital
08/28/2019
According to the Veterans Affairs department, US authorities are investigating suspicious deaths at a veterans hospital in West Virginia.
According to the Veterans Affairs department, US authorities are investigating suspicious deaths at a veterans hospital in West Virginia.
According to the Veterans...
08/28/2019
Veterans Health Today
News
Random Plasma Glucose Tests Predict Diabetes Diagnosis
08/12/2019
“Although screening for prediabetes and diabetes could permit earlier detection and treatment, many in the at-risk population do not receive the necessary screening,” said lead author Mary Rhee, MD, a physician-researcher with the Atlanta...
“Although screening for prediabetes and diabetes could permit earlier detection and treatment, many in the at-risk population do not receive the necessary screening,” said lead author Mary Rhee, MD, a physician-researcher with the Atlanta...
“Although screening for...
08/12/2019
Veterans Health Today
News
Long-Term Metformin Use Among Veteran Population Lowers Incidence of Neurodegenerative Disease
08/05/2019
Among a study population of older adults with type 2 diabetes who were US veterans, researchers found that the use of metformin for more than 2 years was associated with a lower incidence of neurodegenerative disease.
Among a study population of older adults with type 2 diabetes who were US veterans, researchers found that the use of metformin for more than 2 years was associated with a lower incidence of neurodegenerative disease.
Among a study population of...
08/05/2019
Veterans Health Today

Advertisement

News
Added Pimavanserin Shows Positive Trends in Schizophrenia but Misses Primary Endpoint in Trial
07/31/2019
“Unfortunately, we did not achieve a statistically significant reduction in the Positive and Negative Syndrome Scale (PANSS) total score in this study,” said Acadia Pharmaceuticals president Serge Stankovic, MD.
“Unfortunately, we did not achieve a statistically significant reduction in the Positive and Negative Syndrome Scale (PANSS) total score in this study,” said Acadia Pharmaceuticals president Serge Stankovic, MD.
“Unfortunately, we did not...
07/31/2019
Veterans Health Today
News
Improving Survival Among T2D Patients With Pancreatic Cancer, Lymphoma
07/25/2019
Researchers recently identified a treatment associated with a significant, positive effect of increased overall survival in type 2 diabetes patients with pancreatic cancer and lymphoma.
Researchers recently identified a treatment associated with a significant, positive effect of increased overall survival in type 2 diabetes patients with pancreatic cancer and lymphoma.
Researchers recently identified...
07/25/2019
Veterans Health Today
News
Jury Still Out on Best Oral Antipsychotic for Multi-Episode Schizophrenia
07/23/2019
Most oral antipsychotics are effective for acute treatment of multi-episode schizophrenia in adults, but it's not clear which, if any, is best, according to a new network meta-analysis comparing 32 drugs.
Most oral antipsychotics are effective for acute treatment of multi-episode schizophrenia in adults, but it's not clear which, if any, is best, according to a new network meta-analysis comparing 32 drugs.
Most oral antipsychotics are...
07/23/2019
Veterans Health Today

Advertisement

News
Alkermes to Seek Two Indications for ALKS 3831
07/23/2019
Alkermes plc is expanding its New Drug Application (NDA) for the investigational drug ALKS 3831—a combination of the antipsychotic olanzapine and the novel molecular entity samidorphan—to include the treatment of bipolar I disorder as well as...
Alkermes plc is expanding its New Drug Application (NDA) for the investigational drug ALKS 3831—a combination of the antipsychotic olanzapine and the novel molecular entity samidorphan—to include the treatment of bipolar I disorder as well as...
Alkermes plc is expanding its...
07/23/2019
Veterans Health Today
News
Acadia`s Schizophrenia Treatment Misses Late-Stage Main Goal
07/22/2019
Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.
Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.
Acadia Pharmaceuticals Inc said...
07/22/2019
Veterans Health Today
News
Cognitive Decline Continues After Onset of Psychosis
07/17/2019
Cognitive decline continues for years after the onset of schizophrenia and other psychoses, although it varies across cognitive functions and diagnoses, according to a study published online in The American Journal of Psychiatry.
Cognitive decline continues for years after the onset of schizophrenia and other psychoses, although it varies across cognitive functions and diagnoses, according to a study published online in The American Journal of Psychiatry.
Cognitive decline continues for...
07/17/2019
Veterans Health Today

Advertisement

Advertisement

Advertisement

Veterans Health Today Newsletter

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use